---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-038015"
form_type: "8-K"
ticker: "SCYX"
cik: "0001178253"
company_name: "SCYNEXIS INC"
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T05:47:15.524626+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# SCYNEXIS reports FY2023 net income of $67M, driven by $130M GSK license revenue; product revenue down 80%

## Summary
- Net income of $67.0M ($1.40 basic EPS) vs net loss of $62.8M in FY2022; license revenue of $139M vs $103K prior year.
- BREXAFEMME net product revenue fell to $1.0M (from $5.0M); cost of product revenue $15.6M including $14.6M inventory impairment from beta-lactam cross-contamination.
- Cash, equivalents and investments $98.0M at Dec 31, 2023 (up from $73.5M); cash runway >2 years.
- GSK deal total potential value revised to $448M (from $593M); final study reports due H1 2024 trigger $10M milestone payment.
- SCY-247 IND-enabling activities advancing; Phase I initiation expected H2 2024.

## SEC filing metadata
- accession: 0000950170-24-038015
- form_type: 8-K
- ticker: SCYX
- cik: 0001178253
- company_name: SCYNEXIS INC
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178253/000095017024038015/0000950170-24-038015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178253/000095017024038015/scyx-20240328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-038015
- JSON: https://secwatch.observer/filing/0000950170-24-038015.json
- Plain text: https://secwatch.observer/filing/0000950170-24-038015.txt

## Key facts
- Earnings Releases
  SCYNEXIS INC reported the year ended December 31, 2023 results: net income $67.0 million, EPS $1.40 basic income per share.
  - Period: the year ended December 31, 2023
  - Net income: $67.0 million
  - EPS: $1.40 basic income per share
  - Result: reported results
  source text: Net income for the full year 2023, was $67.0 million, or $1.40 basic income per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178253/000095017024038015/0000950170-24-038015-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.